Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells

American Journal of Obstetrics and Gynecology

Volumn 205, Issue 4, 2011, Pages 362.e12-362.e25

  Li, Liang Cheng ^a   Jayaram, Shankar ^a   Ganesh, Lakshmy ^a   Qian, Lixia ^a   Rotmensch, Jacob ^b   Maker, Ajay V ^a   Prabhakar, Bellur S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; C FLIP; IG21; MADD; Ovarian cancer; ShRNA

Indexed keywords

BIOLOGICAL FACTOR; FLICE INHIBITORY PROTEIN; PROTEIN MADD; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CFLAR PROTEIN, HUMAN; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MADD PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; FEMALE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; FEMALE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; OVARIAN NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED;

EID: 84855163005     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2011.05.035     Document Type: Article

References (51)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Qazi F, McGuire WP. The treatment of epithelial ovarian cancer. CA Cancer J Clin 1995; 45:88-101.
3. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82. (Pubitemid 26091143)
4. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63. (Pubitemid 29068521)
5. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603. (Pubitemid 39025054)
6. Schug ZT, Gonzalvez F, Houtkooper RH, Vaz FM, Gottlieb E. BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. Cell Death Differ 2011;18:538-48.
7. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. BID, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-90. (Pubitemid 28391864)
8. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501. (Pubitemid 28391865)
9. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90. (Pubitemid 26175834)
10. Peter ME. The flip side of FLIP. Biochem J 2004;382:e1-3.
11. Safa AR, Day TW, Wu CH. Cellular FLICElike inhibitory protein (c-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets 2008;8:37-46. (Pubitemid 351237908)
12. Lin Y, Liu X, Yue P, et al. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther 2008;7:3556-65.
13. Sun SY, Yue P, Zhou JY, et al. Overexpression of Bcl2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun 2001;280:788-97. (Pubitemid 32924499)
14. Taniai M, Grambihler A, Higuchi H, et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004; 64:3517-24. (Pubitemid 38657926)
15. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004; 11:915-23. (Pubitemid 39139750)
16. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999;274:1541-8.
17. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5. (Pubitemid 27297457)
18. Al-Zoubi AM, Efimova EV, Kaithamana S, et al. Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on tumor necrosis factor alpha-induced apoptosis and activation of caspase-8 and -3. J Biol Chem 2001;276: 47202-11.
19. Chow VT, Lee SS. DENN, a novel human gene differentially expressed in normal and neoplastic cells. DNA Seq 1996;6:263-73. (Pubitemid 27084514)
20. Mulherkar N, Ramaswamy M, Mordi DC, Prabhakar BS. MADD/DENN splice variant of the IG20 gene is necessary and sufficient for cancer cell survival. Oncogene 2006;25:6252-61. (Pubitemid 44564742)
21. Li LC, Sheng JR, Mulherkar N, Prabhakar BS, Meriggioli MN. Regulation of apoptosis and caspase-8 expression in neuroblastoma cells by isoforms of the IG20 gene. Cancer Res 2008;68:7352-61.
22. Subramanian M, Pilli T, Bhattacharya P, et al. Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. J Clin Endocrinol Metab 2009;94:1467-71.
23. Mulherkar N, Prasad KV, Prabhakar BS. MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation: knockdown enhances TRAIL-induced apoptosis of cancer cells. J Biol Chem 2007;282:11715-21. (Pubitemid 47100706)
24. Li P, Jayarama S, Ganesh L, et al. Aktphosphorylated mitogen-activated kinaseactivating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4. J Biol Chem 2010;285:22713-22.
25. Lee MT, Coburn GA, McClure MO, Cullen BR. Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat-or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol 2003;77:11964-72. (Pubitemid 37339850)
26. Simon P. Q-gene: processing quantitative real-time RT-PCR data. Bioinformatics 2003; 19:1439-40. (Pubitemid 36939825)
27. Ramaswamy M, Efimova EV, Martinez O, Mulherkar NU, Singh SP, Prabhakar BS. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAILinduced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC. Oncogene 2004;23:6083-94. (Pubitemid 39178861)
28. Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004;10:7439-49. (Pubitemid 39557505)
29. Lancaster JM, Sayer R, Blanchette C, et al. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res 2003;9:762-6. (Pubitemid 36182612)
30. Prabhakar BS, Mulherkar N, Prasad KV. Role of IG20 splice variants in TRAIL resistance. Clin Cancer Res 2008;14:347-51. (Pubitemid 351226099)
31. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
32. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-60. (Pubitemid 29164042)
33. Vignati S, Codegoni A, Polato F, Broggini M. Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur J Cancer 2002;38:177-83. (Pubitemid 34031834)
34. Bevis KS, Buchsbaum DJ, Straughn JM Jr. Overcoming TRAIL resistance in ovarian carcinoma. Gynecol Oncol 2010;119:157-63.
35. Ashkenazi A. Directing cancer cells to selfdestruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001-12.
36. Bodmer JL, Holler N, Reynard S, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000;2:241-3.
37. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12:599-609.
38. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and Immunity 2000;12:611-20.
39. Boatright KM, Renatus M, Scott FL, et al. A unified model for apical caspase activation. Mol Cell 2003;11:529-41. (Pubitemid 36293843)
40. Walczak H, Sprick MR. Biochemistry and function of the DISC. Trends Biochem Sci 2001;26:452-3. (Pubitemid 32607488)
41. Horak P, Pils D, Kaider A, et al. Perturbation of the tumor necrosis factor-related apoptosisinducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res 2005;11:8585-91. (Pubitemid 43005904)
42. El-Gazzar A, Wittinger M, Perco P, et al. The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential. Gynecol Oncol 2010;117:451-9.
43. Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piche A. The inhibition of Bid expression by Akt leads to resistance to TRAILinduced apoptosis in ovarian cancer cells. Oncogene 2010;29:5523-36.
44. Efimova EV, Al-Zoubi AM, Martinez O, et al. IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs. Oncogene 2004;23:1076-87. (Pubitemid 38269961)
45. Lurie G, Wilkens LR, Thompson PJ, Matsuno RK, Carney ME, Goodman MT. Symptom presentation in invasive ovarian carcinoma by tumor histological type and grade in a multiethnic population: a case analysis. Gynecol Oncol 2010;119:278-84.
46. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1-and CD-95-induced apoptosis. J Biol Chem 1997;272:17255-7. (Pubitemid 27311147)
47. Liu X, Yue P, Schonthal AH, Khuri FR, Sun SY. Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. Cancer Res 2006;66:11115-9. (Pubitemid 46009936)
48. Lai LJ, Ho TC. Pigment epithelial-derived factor inhibits c-FLIP expression and assists ciglitazone-induced apoptosis in hepatocellular carcinoma. Anticancer Res 2011;31: 1173-80.
49. Lee SJ, Noh HJ, Sung EG, et al. Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins. Int J Oncol 2011; 38:485-92.
50. Bleumink M, Kohler R, Giaisi M, Proksch P, Krammer PH, Li-Weber M. Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression. Cell Death Differ 2011;18:362-70.
51. Murtaza I, Saleem M, Adhami VM, Hafeez BB, Mukhtar H. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res 2009;69:1156-65.